1. Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
2. Fukuoka M, Yano S, Giaccone G, et al: Final results from a phase II trial of ZD1839 (′Iressa') for patients with advanced non-small cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 21:298a,2002, (abstr 1188)
3. Kris MG, Natale RB, Herbst R, et al: A phase II trial of ZD1839 (′Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21:292a,2002, (abstr 1166)